10-Q · May 7, 2026
Palvella Therapeutics reported a significant net loss of $15.8 million for Q1 2026, an increase of approximately 93% from the prior year’s loss of $8.2 million. Operating expenses surged due to increased research and…
Earnings analysis · 10-Q
PVLA earnings analysis
Filed August 4, 2026 · Our reading of the company's report
The latest report
Palvella remains a pre-revenue clinical-stage biotechnology company, so revenue, gross margin, operating margin, segment revenue, and free cash flow were not reported. Q2 net loss rose to $21.9 million from $9.5 million…
Read full summary
Palvella remains a pre-revenue clinical-stage biotechnology company, so revenue, gross margin, operating margin, segment revenue, and free cash flow were not reported. Q2 net loss rose to $21.9 million from $9.5 million and diluted EPS was -$1.52, worsening from -$0.86 a year ago and -$1.20 in Q1 2026, driven by sharply higher R&D and public-company G&A costs. Offsetting the losses, the company ended June with $250.6 million of cash and short-term investments after a $215.8 million net equity raise, and it advanced its lead program into rolling NDA submission; however, the cutaneous-VM Breakthrough Therapy Designation was not granted.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.52
What stood out
-
NDA process advances on strong SELVA data
The company completed a pre-NDA meeting, received FDA rolling-review authorization, and submitted the first NDA module in June 2026. The SELVA Phase 3 study produced a +2.13-point mean mLM-IGA improvement in the ITT population (n=49; p<0.001), with 86% (37/43) rated Much or Very Much Improved at Week 24.
-
Liquidity strengthened by $215.8M financing
Cash, cash equivalents and short-term investments were $250.6 million at June 30, 2026, following $215.8 million of net proceeds from the February equity offering. Management states this liquidity is sufficient to fund planned operations for at least the next 12 months.
-
Pipeline expands beyond lead NDA program
Clinical pipeline execution broadened: the LOTU Phase 2 angiokeratoma study dosed its first patients in April 2026, with topline results expected in H2 2027. The company also plans to initiate its DSAP Phase 2 trial in H2 2026.
-
Cash resources support near-term development
Operating cash use was $23.7 million in the first six months of 2026, while period-end liquidity was $250.6 million. The resulting cash position supports continued investment toward the planned H1 2027 launch, if approved.
What to watch
-
Losses and EPS deterioration accelerated
The Q2 net loss widened to $21.9 million from $9.5 million a year earlier, while diluted EPS worsened to -$1.52 from -$0.86. Sequentially, EPS also deteriorated by $0.32 from -$1.20 in Q1 2026.
-
Expense base rose sharply ahead of revenue
Q2 R&D expense increased $7.4 million year over year to $12.5 million, and G&A increased $4.8 million to $8.9 million. Management expects R&D expense to increase substantially as late-stage development, regulatory work, and commercialization preparation continue.
-
Cutaneous-VM regulatory designation was denied
FDA did not grant Breakthrough Therapy Designation for the cutaneous-VM program in July 2026; management plans to resubmit using patient interviews and new 24-week data. The planned pivotal Phase 3 trial is not expected to commence until Q4 2026.
-
Operating cash burn nearly doubled
The company reported $23.7 million of operating cash outflow for the first six months of 2026, up from $12.2 million in the prior-year period. It has no commercial revenue and says it may need additional capital beyond the stated 12-month liquidity horizon.
-
No risk-factor updates; royalty obligations remain
Item 1A states there were no material changes to risk factors from the 2025 Form 10-K. Nevertheless, the filing identifies up to $5.0 million of remaining Ligand milestone obligations and royalties of 8.0% to 9.8% of worldwide QTORIN rapamycin net sales.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q. Management remains on track to complete the rolling NDA submission for QTORIN rapamycin in H2 2026, expects to commence the cutaneous-VM Phase 3 trial in Q4 2026, anticipates initiating the DSAP Phase 2 study in H2 2026, and is preparing for a planned standalone U.S. microcystic-LM launch in H1 2027, subject to FDA approval.
Earlier filings 4
10-K · March 31, 2026
Palvella’s 10-K centers on clinical progress for its QTORIN platform, highlighted by positive Phase 3 SELVA results for QTORIN 3.9% rapamycin (mLM-IGA +2.13, p<0.001) and Phase 2 TOIVA positive topline data in cutaneous…
10-Q · August 14, 2025
Palvella reported widening losses in Q2: operating expenses rose to $9,250 (three months ended June 30, 2025) and net loss was $(9,471) vs $(4,172) in Q2 2024. Cash and cash equivalents were $70,433 at June 30, 2025 and…
10-Q · May 15, 2025
Palvella reported a widening GAAP net loss of $8.185 million for the quarter ended March 31, 2025 (vs $2.536 million in Q1 2024) on operating expenses that rose to $7.871 million (from $1.759 million). Cash and cash…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.